Page last updated: 2024-11-05
troglitazone and Acute Lymphoid Leukemia
troglitazone has been researched along with Acute Lymphoid Leukemia in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Jardine, L | 1 |
| Hambleton, S | 1 |
| Bigley, V | 1 |
| Pagan, S | 1 |
| Wang, XN | 1 |
| Collin, M | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| A Phase II Trial of Nonmyeloablative Haploidentical Peripheral Blood Stem Cell Transplantation Followed By Maintenance Therapy With the Novel Oral Proteasome Inhibitor, MLN9708, in Patients With High-risk Hematologic Malignancies[NCT02169791] | Phase 2 | 29 participants (Actual) | Interventional | 2014-07-15 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Day 30 CD3 Donor Chimerism
To measure CD3 donor chimerism post-transplant (NCT02169791)
Timeframe: 30 days
| Intervention | percentage of chimerism (Median) |
|---|
| Haploidentical Transplant | 100 |
Day 30 CD33 Donor Chimerism
To measure CD33 donor chimerism at Day 30 (NCT02169791)
Timeframe: 30 days
| Intervention | percentage of chimerism (Median) |
|---|
| Haploidentical Transplant | 100 |
Graft Versus Host Disease
To measure days to onset of acute graft versus host disease (NCT02169791)
Timeframe: 100 days
| Intervention | days (Median) |
|---|
| Haploidentical Transplant | 28.5 |
Neutrophil Engraftment
To obtain time to neutrophil engraftment post-transplant (NCT02169791)
Timeframe: 1 year
| Intervention | days (Median) |
|---|
| Haploidentical Transplant | 16 |
Number of Participants Experiencing Relapse or Progression
To estimate the incidence of relapse/progression at one-year post-transplant. (NCT02169791)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|
| Haploidentical Transplant | 10 |
Time to Platelet Recovery Post Transplant
To measure the time to platelet recovery post-transplant (NCT02169791)
Timeframe: 1 year
| Intervention | days (Median) |
|---|
| Haploidentical Transplant | 29 |
Other Studies
1 other study available for troglitazone and Acute Lymphoid Leukemia